• [Expert consensus on the diagnosis and treatment of young breast cancer in China (2022 Edition)].
    • Chinese Society of Clinical Oncology, Experts Committee on Breast Cancer; China Anti-Cancer Association, the Society of Breast Cancer; Chinese Medical Association, Chinese Society of Breast Surgery.
    • Zhonghua Yi Xue Za Zhi. 2023 Feb 14;103(6):387-403. Chinese. doi: 10.3760/cma.j.cn112137-20220907-01895.
    • [Article in Chinese]
    • Challenges in periodic revision of genetic testing results: comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 Variants of Uncertain Significance.
    • Finger Andreis T, Isabel Weber de Souza K, Araujo Vieira I, Alemar B, Sinigaglia M, Marinho de Araújo Rocha Y, Artigalás O, Bittar C, Brinckmann Oliveira Netto C, Ashton-Prolla P, Rosset C.
    • Gene. 2023 Feb 10:147281. doi: 10.1016/j.gene.2023.147281. Epub ahead of print.
    • Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    • Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
    • Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26.
    • Review
    • Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
    • Garcia-Pelaez J, Barbosa-Matos R, Lobo S, Dias A, Garrido L, Castedo S, Sousa S, Pinheiro H, Sousa L, Monteiro R, Maqueda JJ, Fernandes S, Carneiro F, Pinto N, Lemos C, Pinto C, Teixeira MR, Aretz S, Bajalica-Lagercrantz S, Balmaña J, Blatnik A, Benusiglio PR, Blanluet M, Bours V, Brems H, Brunet J, Calistri D, Capellá G, Carrera S, Colas C, Dahan K, de Putter R, Desseignés C, Domínguez-Garrido E, Egas C, Evans DG, Feret D, Fewings E, Fitzgerald RC, Coulet F, Garcia-Barcina M, Genuardi M, Golmard L, Hackmann K, Hanson H, Holinski-Feder E, Hüneburg R, Krajc M, Lagerstedt-Robinson K, Lázaro C, Ligtenberg MJL, Martínez-Bouzas C, Merino S, Michils G, Novakovic S, Patiño-García A, Ranzani GN, Schröck E, Silva I, Silveira C, Soto JL, Spier I, Steinke-Lange V, Tedaldi G, Tejada MI, Woodward ER, Tischkowitz M, Hoogerbrugge N, Oliveira C.
    • Lancet Oncol. 2022 Nov 24:S1470-2045(22)00643-X. doi: 10.1016/S1470-2045(22)00643-X. Epub ahead of print.
    • An evidence-based practice guideline of the National Society of Genetic Counselors for telehealth genetic counseling.
    • Green S, Hartzfeld D, Terry AB, Fissell K, Friedman S, Paolino N, Principe K, Sandbach J, Trzupek K, Winheld S, Malinowski J.
    • J Genet Couns. 2022 Aug 30. doi: 10.1002/jgc4.1627. Epub ahead of print.
    • Guideline
    • Practice guidelines for BRCA1/2 tumour testing in ovarian cancer.
    • Grafodatskaya D, O'Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, McCready E, Parboosingh J, Spriggs EL, Vaags AK, Stockley TL.
    • J Med Genet. 2022 Aug;59(8):727-736. doi: 10.1136/jmedgenet-2021-108238. Epub 2022 Apr 7.
    • Educational Programme for Cancer Nurses in Genetics, Health Behaviors and Cancer Prevention: A Multidisciplinary Consensus Study.
    • Diez de Los Rios de la Serna C, Fernández-Ortega P, Lluch-Canut T.
    • J Pers Med. 2022 Jul 5;12(7):1104. doi: 10.3390/jpm12071104.
    • Preimplantation genetic testing in patients with genetic susceptibility to cancer.
    • Villy MC, Frydman N, Moutou C, Thierry G, Raad J, Colas C, Steffann J, Metras J, Chabbert-Buffet N, Parc Y, Richard S, Benusiglio PR.
    • Fam Cancer. 2022 Apr 12. doi: 10.1007/s10689-022-00293-1. Epub ahead of print.
    • BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.
    • Petrova D, Cruz M, Sánchez MJ.
    • Breast. 2022 Feb;61:66-76. doi: 10.1016/j.breast.2021.12.005. Epub 2021 Dec 11.
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    • Creating Breast and Gynecologic Cancer Guidelines for Transgender Patients With BRCA Mutations.
    • Bedrick BS, Fruhauf TF, Martin SJ, Ferriss JS.
    • Obstet Gynecol. 2021 Dec 1;138(6):911-917. doi: 10.1097/AOG.0000000000004597.
    • Commentary
    • Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    • Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3.
    • Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1.
    • Review
    • Genetic counseling clinical documentation: Practice Resource of the National Society of Genetic Counselors.
    • Hunt Brendish K, Patel D, Yu K, Alexander CK, Lemons J, Gunter A, Carmany EP.
    • J Genet Couns. 2021 Oct;30(5):1336-1353. doi: 10.1002/jgc4.1491. Epub 2021 Aug 14.
    • Heart Rate Variability-Guided Exercise During Chemotherapy in Triathlete with Stage 1 BRCA1-Mutated Breast Cancer.
    • Talbot A, McCabe M, Daly B, Gallagher D.
    • Ir Med J. 2021 Aug 19;114(7):420.
    • Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks.
    • Meier F, Harney A, Rhiem K, Neusser S, Neumann A, Braun M, Wasem J, Huster S, Dabrock P, Schmutzler RK.
    • Recent Results Cancer Res. 2021 [First Online: 22 May 2021];218:47-66. doi: 10.1007/978-3-030-63749-1_5.
    • eBook chapter
    • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    • Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H.
    • Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.
    • Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    • Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM.
    • Int J Mol Sci. 2021 Apr 4;22(7):3753. doi: 10.3390/ijms22073753.
    • British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom.
    • Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood NJ, Ghaem-Maghami S, Miles T, Ganesan R.
    • Int J Gynecol Cancer. 2021 Jan 19:ijgc-2020-002112. doi: 10.1136/ijgc-2020-002112. Epub ahead of print.
    • Guidelines. Review.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Genetics and the Gynecologic Patient.
    • Wade KS, Estes JM, Kline RC.
    • Ochsner J. 2020 Winter;20(4):446-451. doi: 10.31486/toj.20.0051.
    • Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy.
    • Ray T.
    • Precision Oncology News. 2020 Nov 25.
    • Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.
    • Vargas-Parra G, Del Valle J, Rofes P, Gausachs M, Stradella A, Moreno-Cabrera JM, Velasco A, Tornero E, Menéndez M, Muñoz X, Iglesias S, López-Doriga A, Azuara D, Campos O, Cuesta R, Darder E, de Cid R, González S, Teulé A, Navarro M, Brunet J, Capellá G, Pineda M, Feliubadaló L, Lázaro C.
    • Hum Mutat. 2020 Sep 9. doi: 10.1002/humu.24110. Epub ahead of print.
    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
    • Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A.
    • JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.
    • Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.
    • Hered Cancer Clin Pract. 2020 Jun 6;18:13. doi: 10.1186/s13053-020-00144-z.
    • Studies Show Potential of Video, Online Education to Expand Cancer Risk Genetic Test Access.
    • Ray T.
    • Precision Oncology News. 2020 Jun 4.
    • Press
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    • González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2019 Dec 30. doi: 10.1007/s12094-019-02262-0. [Epub ahead of print]
    • Heartbreaking News, Then Tumor Find Leads to Genetic Testing.
    • Hackethal V.
    • Medscape Oncology. 2019 Dec 27.

    Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, NCCN Guidelines Version 1.2020. (NCCN.org. 2019 Dec 4. Version 1.2020.)

    • USPSTF guideline: Offer risk-reducing drugs to women at increased risk for breast cancer and low risk for adverse effects.
    • Batur P.
    • Ann Intern Med. 2019 Dec 17;171(12):JC62. doi: 10.7326/ACPJ201912170-062.
    • Review

    Practice Guidelines:

    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.

    • Study: Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Dec 6.

    Original research:

    Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: a cohort study of women selected for familial and genetic risk.

    • Image-based screening for men at high risk for breast cancer: Benefits and drawbacks.
    • Woods RW, Salkowski LR, Elezaby M, Burnside ES, Strigel RM, Fowler AM.
    • Clin Imaging. 2019 Nov 28;60(1):84-89. doi: 10.1016/j.clinimag.2019.11.005. [Epub ahead of print]
    • Review
    • [What attitude to women at high risk of breast cancer?]
    • Livon D, Moretta J, Noguès C.
    • Presse Med. 2019 Nov 6. pii: S0755-4982(19)30302-1. doi: 10.1016/j.lpm.2019.07.014. [Epub ahead of print]
    • Review, [Article in French]
    • 2019 exceptional surveillance of familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (NICE guideline CG164) [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Haynes C.
    • London: National Institute for Health and Care Excellence (UK); 2019 Nov.
    • Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
    • [No author given]
    • National Institute for Health and Care Excellence (UK): Clinical Guidelines; 2013 Jun. [Last Update: November 2019.]
    • Calling on Primary Care to Prevent BRCA-Related Cancers.
    • Armstrong K.
    • J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05469-7. [Epub ahead of print]
    • Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB.
    • JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885.

    Guidelines:

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Editorial:

    Medications to Reduce Breast Cancer Risk: Promise and Limitations.

    Patient Page:

    Medications to Reduce Breast Cancer Risk.

    Audio Interview/CME: USPSTF Recommendation: Medication Use to Reduce Risk of Breast Cancer. (JN Learning)

    Review:

    USPSTF guideline: Offer risk-reducing drugs to women at increased risk for breast cancer and low risk for adverse effects.

    • Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
    • Ademuyiwa FO, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher K, Bierut LJ.
    • Breast Cancer Res Treat. 2019 Jul 19. doi: 10.1007/s10549-019-05359-w. [Epub ahead of print]
    • Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    • So MK, Jeong TD, Lim W, Moon BI, Paik NS, Kim SC, Huh J.
    • Breast Cancer. 2019 Jul;26(4):510-519. doi: 10.1007/s12282-019-00951-w. Epub 2019 Feb 6.
    • [Hereditary Breast and Ovarian Cancer Syndrome].
    • Inuzuka M, Nakamura S.
    • Gan To Kagaku Ryoho. 2019 Jul;46(7):1109-1113.
    • Review, [Article in Japanese]
    • Structural Aberrations with Secondary Implications (SASIs): consensus recommendations for reporting of cancer susceptibility genes identified during analysis of Copy Number Variants (CNVs).
    • Talukdar S, Hawkes L, Hanson H, Kulkarni A, Brady AF, McMullan DJ, Ahn JW, Woodward E, Turnbull C; UK Association for Clinical Genomic Science and UK Cancer Genetics Group.
    • J Med Genet. 2019 Apr 24. pii: jmedgenet-2018-105820. doi: 10.1136/jmedgenet-2018-105820. [Epub ahead of print]
    • Guidelines
    • Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report.
    • Spurdle AB, Greville-Heygate S, Antoniou AC, Brown M, Burke L, de la Hoya M, Domchek S, Dörk T, Firth HV, Monteiro AN, Mensenkamp A, Parsons MT, Radice P, Robson M, Tischkowitz M, Tudini E, Turnbull C, Vreeswijk MP, Walker LC, Tavtigian S, Eccles DM.
    • J Med Genet. 2019 Apr 8. pii: jmedgenet-2018-105872. doi: 10.1136/jmedgenet-2018-105872. [Epub ahead of print]
    • Review, Guidelines
    • A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.
    • Forbes C, Fayter D, de Kock S, Quek RG.
    • Cancer Manag Res. 2019 Mar 22;11:2321-2337. doi: 10.2147/CMAR.S189627. eCollection 2019.
    • Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework.
    • Green RF, Ari M, Kolor K, Dotson WD, Bowen S, Habarta N, Rodriguez JL, Richardson LC, Khoury MJ.
    • Genet Med. 2019 Jan;21(1):28-37. doi: 10.1038/s41436-018-0028-2. Epub 2018 Jun 15.
    • Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study.
    • Krishnamachari B, Rehman M, Cohn JE, Chan V, Modi N, Leitner O, Tangney K, O'Connor A, Blazey W, Koehler S, Tegay D.
    • J Cancer Educ. 2018 Dec;33(6):1213-1221. doi: 10.1007/s13187-017-1233-4.
    • Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
    • Lee JS, Oh S, Park SK, Lee MH, Lee JW, Kim SW, Son BH, Noh DY, Lee JE, Park HL, Kim MJ, Cho SI, Lee YK, Park SS, Seong MW.
    • J Med Genet. 2018 Dec;55(12):794-802. doi: 10.1136/jmedgenet-2018-105565. Epub 2018 Nov 10.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • New Breast Cancer Screening Guidelines Build on Progress.
    • Larsen Haidle J.
    • NSGC blog, 2018 Oct 1.

    Guidelines: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Genetic/Familial High-Risk Assessment: Breast and Ovarian (PDF) (NCCN.org)

    • Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    • Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST.
    • Contemp Clin Trials. 2018 Oct;73:123-135. doi: 10.1016/j.cct.2018.09.005. Epub 2018 Sep 18.
    • The National Comprehensive Cancer Network (NCCN) Guidelines Have Been Updated: Here is What You Need to Know.
    • [No author given]
    • My Gene Counsel. 2018 Jul 23.

    Guidelines: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Genetic/Familial High-Risk Assessment: Breast and Ovarian (PDF) (NCCN.org)

    • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Genetic/Familial High-Risk Assessment: Breast and Ovarian
    • Daly MB, Pilarski R, Berry M, Buys SS, Friedman S, Garber JE, Hutton ML, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Laronga C, Litton JK, Madlensky L, Mac JS, Merajver SD, Offit K, Pal T, Peterson HJ, Reiser G, Shannon KM, Thaker P, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Darlow S.
    • NCCN.org. 2018 Jul 11. Version 1.2019.
    • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.
    • Untch M, Würstlein R, Marschner N, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Harbeck N, Thomssen C.
    • Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4.
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • Complexities of Variant Classification in Clinical Hereditary Cancer Genetic Testing.
    • Mundt E, Nix P, Brown K, Bowles KR, Manley S.
    • J Clin Oncol. 2017 Dec 1;35(34):3796-3799. doi: 10.1200/JCO.2017.74.5182. Epub 2017 Oct 5.
    • Identification and management of familial breast cancer in Austria.
    • Singer CF, Tan YY, Rappaport C.
    • Horm Mol Biol Clin Investig. 2017 Nov 30;32(2). pii: /j/hmbci.2017.32.issue-2/hmbci-2017-0025/hmbci-2017-0025.xml. doi: 10.1515/hmbci-2017-0025.
    • Review
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants. Available Clinical Practice Guidelines for Hereditary Breast and Ovarian Cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • The National Comprehensive Cancer Network (NCCN) Guidelines Have Updated: Here is What You Need to Know.
    • [No author given]
    • My Gene Counsel. 2017 Oct 4.
    • Integrating surgery and genetic testing for the modern surgeon.
    • Caso R, Beamer M, Lofthus AD, Sosin M.
    • Ann Transl Med. 2017 Oct;5(20):399. doi: 10.21037/atm.2017.06.50.
    • New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer.
    • Robinson T, Janssen A, Kirk J, DeFazio A, Goodwin A, Tucker K, Shaw T.
    • J Cancer Educ. 2017 Sep;32(3):476-482. doi: 10.1007/s13187-015-0944-7.
    • Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
    • Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology.
    • Obstet Gynecol. 2017 Sep;130(3):e110-e126. doi: 10.1097/AOG.0000000000002296.
    • Guidelines

    Summary:

    Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.

    • Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    • Committee on Gynecologic Practice, Society of Gynecologic Oncology.
    • Obstet Gynecol. 2017 Sep;130(3):e146-e149. doi: 10.1097/AOG.0000000000002299.

    Summary:

    Committee Opinion No. 716 Summary: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.

    • [Genetic Counseling of HBOC and Japanese Organization of HBOC].
    • Fukushima Y.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):107-110.
    • Review, [Article in Japanese]
    • November Webinar, The NCCN Guidelines: How They're Created and Updated.
    • Heather Hampel, Robert Pilarski
    • NSGC. Cancer SIG Webinar Recordings. 2016 Nov 18.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: November webinar slides and recording are available

    • Genetic testing and interpretive complexity: a BRCA1 gene mutation example.
    • Gogarty DS, Farrell MP, Gallagher DJ.
    • Ir J Med Sci. 2016 Nov;185(4):955-957. Epub 2014 Dec 13.
    • Case report, Review
    • Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    • Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K.
    • Am J Clin Oncol. 2016 Aug;39(4):363-7. doi: 10.1097/COC.0000000000000073.
    • Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
    • Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17.
    • Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine.
    • Levine DA, Karlan BY, Strauss JF 3rd.
    • JAMA. 2016 May 10;315(18):1943-4. doi: 10.1001/jama.2016.2640.
    • Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    • Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, Wubbenhorst B, Ravichandran V, Moore RM, Hu C, Guidugli L, Wenz B, Domchek SM, Robson ME, Szabo C, Neuhausen SL, Weitzel JN, Offit K, Couch FJ, Nathanson KL.
    • Am J Hum Genet. 2016 May 5;98(5):801-817. doi: 10.1016/j.ajhg.2016.02.024.
    • The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound.
    • Mueller-Schimpfle MP, Brandenbusch VC, Degenhardt F, Duda V, Madjar H, Mundinger A, Rathmann R, Hahn M.
    • Ultraschall Med. 2016 Apr;37(2):170-175. Epub 2016 Feb 16.
    • Review
    • NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.
    • Tucker H, Charles Z, Robertson J, Adam J.
    • Lancet Oncol. 2016 Mar;17(3):277-8. doi: 10.1016/S1470-2045(16)00062-0. Epub 2016 Jan 27.
    • News
    • Committee Opinion No. 659 Summary: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.
    • [No authors listed]
    • Obstet Gynecol. 2016 Mar;127(3):618-9. doi: 10.1097/AOG.0000000000001349.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ACOG opinion Vaginal estrogen and women with ER pos breast ca

    • Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    • Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, Potter D, Schroeder C, Tyczynski JE, Gomez Garcia EB.
    • Adv Ther. 2016 Feb;33(2):129-50. doi: 10.1007/s12325-016-0281-1. Epub 2016 Jan 25.
    • Review
    • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    • Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S.
    • J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: NCCN High-Risk Breast-Ovarian Guidelines 1.2016

    • Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2.
    • Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS.
    • Semin Radiat Oncol. 2016 Jan;26(1):3-8. doi: 10.1016/j.semradonc.2015.09.004. Epub 2015 Sep 4.
    • [Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].
    • Foretová L, Macháčková E, Palácová M, Navrátilová M, Svoboda M, Petráková K.
    • Klin Onkol. 2015 Winter;29 Suppl 1:9-13.
    • Review, [Article in Czech]
    • SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
    • Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2015 Dec;17(12):956-61. doi: 10.1007/s12094-015-1435-3. Epub 2015 Dec 15.
    • Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    • Appel SJ, Cleiment RJ.
    • J Natl Black Nurses Assoc. 2015 Dec;26(2):17-26.
    • Breast Cancer, Version 1.2016.
    • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.
    • Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
    • Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, Helbich TH.
    • Wien Klin Wochenschr. 2015 Dec;127(23-24):981-6. doi: 10.1007/s00508-015-0880-x. Epub 2015 Nov 2.
    • Singapore Cancer Network (SCAN) Guidelines for Referral for Genetic Evaluation of Common Hereditary Cancer Syndromes.
    • [No authors listed]
    • Ann Acad Med Singapore. 2015 Oct;44(10):492-510.
    • Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.
    • Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO.
    • Genet Med. 2015 Sep 2;17(9):726-32. doi: 10.1038/gim.2014.183. Epub 2014 Dec 11.
    • BRCA2-associated pancreatic cancer and current screening guidelines.
    • Kasi PM, Pedersen KS, McWilliams RR.
    • Cancer. 2015 Sep 1;121(17):3046. doi: 10.1002/cncr.29447. Epub 2015 May 27.
    • Comment, Letter

    Comment:

    Reply to BRCA2-associated pancreatic cancer and current screening guidelines.

    • Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.
    • Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA Jr.
    • Breast. 2015 Aug;24(4):513-23. doi: 10.1016/j.breast.2015.02.031. Epub 2015 Mar 25.
    • Review
    • AGO Austria recommendations for genetic testing of patients with ovarian cancer.
    • Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.
    • Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.
    • Management of women at high risk of hereditary breast cancer in the Veneto Regional Program for Prevention.
    • Del Sole A, Cinquetti S, Fedato C, Montagna M, Russo F, Sbrogiò LG, Zorzi M.
    • Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):99-101.
    • AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015.
    • Hanf V, Schütz F, Liedtke C, Thill M; AGO Breast Committee.
    • Breast Care (Basel). 2015 Jul;10(3):189-97. doi: 10.1159/000431346. Epub 2015 Jun 18.
    • Practice Guideline
    • Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    • Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.
    • J Natl Cancer Inst. 2015 May 8;107(7). pii: djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.
    • Breast Cancer Risk Reduction, Version 2.2015.
    • Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.
    • Practice guideline
    • Barriers to the Use of Breast Cancer Risk Reduction Therapies.
    • Bambhroliya A, Chavez-MacGregor M, Brewster AM.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):927-35.
    • Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.
    • van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.
    • Eur J Hum Genet. 2015 May;23(5):588-595. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.
    • Clinical management of women at high risk of breast cancer.
    • Wuttke M, Phillips KA.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):6-13. doi: 10.1097/GCO.0000000000000140.
    • Review
    • American BRCA Outcomes and Utilization of Testing (ABOUT) Study: A Pragmatic Research Model that Incorporates Personalized Medicine/Patient-Centered Outcomes in a Real World Setting.
    • Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Teten RT, Kondoff MR, Molina AD, Abdollahian M, Brand L, Walker GS, Sutphen R.
    • J Genet Couns. 2015 Feb;24(1):18-28. doi: 10.1007/s10897-014-9750-3. Epub 2014 Sep 12.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Recommendation Statement.
    • [No authors listed]
    • Am Fam Physician. 2015 Jan 15;91(2):Online.
    • Differences in BRCA counseling and testing practices based on ordering provider type.
    • Cragun D, Camperlengo L, Robinson E, Caldwell M, Kim J, Phelan C, Monteiro AN, Vadaparampil ST, Sellers TA, Pal T.
    • Genet Med. 2015 Jan;17(1):51-57. doi: 10.1038/gim.2014.75. Epub 2014 Jun 12.

    Press: Involving a genetic health care professional may improve quality, reduce unnecessary testing. (Science Daily)

    Press: Survey: Genetic Counseling Leads Some Patients to Cheaper BRCA Tests. (GenomeWeb)

    Blog post: Survey: Genetic Counseling Leads Some Patients to Cheaper BRCA Tests. (Yale Cancer Genetic Counseling)

    • Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
    • Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee.
    • Gynecol Oncol. 2015 Jan;136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009. Epub 2014 Sep 17.
    • Practice Guideline, SGO Position Statement
    • Hereditary breast cancer syndromes and genetic testing.
    • Rich TA, Woodson AH, Litton J, Arun B.
    • J Surg Oncol. 2015 Jan;111(1):66-80. doi: 10.1002/jso.23791. Epub 2014 Nov 7.
    • Review
    • Committee opinion no. 620: salpingectomy for ovarian cancer prevention.
    • [No authors listed]
    • Obstet Gynecol. 2015 Jan;125(1):279-81. doi: 10.1097/01.AOG.0000459871.88564.09.
    • The importance to update the guidelines for the use of genetic testing in noncancer patients in Brazil.
    • Lajus TB.
    • Rev Saude Publica. 2015;49:71. doi: 10.1590/S0034-8910.2015049005988. Epub 2015 Oct 13.
    • Can breast surgeons provide breast cancer genetic testing? An American Society of Breast Surgeons survey.
    • Beitsch PD, Whitworth PW.
    • Ann Surg Oncol. 2014 Dec;21(13):4104-8. doi: 10.1245/s10434-014-3711-9. Epub 2014 Apr 23.

    Comment, Editorial:

    Yes, breast surgeons may provide breast cancer genetic assessment and testing.

    Blog post: Article Concluding the Majority of Breast Surgeons Provide Adequate Genetic Counseling Demonstrates the Opposite. (Yale Cancer Genetic Counseling)

    • Genetics and BRCA in Primary Care.
    • Katherine Kolor.
    • Medscape Oncology, CDC Expert Commentary, 2014 Oct 13.
    • Hormonal and Surgical Treatment in Trans-Women with BRCA1 Mutations: A Controversial Topic.
    • Colebunders B, T'Sjoen G, Weyers S, Monstrey S.
    • J Sex Med. 2014 Oct;11(10):2496-9. doi: 10.1111/jsm.12628. Epub 2014 Jul 10.
    • Case report

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • Risk determination and prevention of breast cancer.
    • Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN.
    • Breast Cancer Res. 2014 Sep 28;16(5):446. doi: 10.1186/s13058-014-0446-2.
    • Genetic/Familial high-risk assessment: breast and ovarian, version 1.2014.
    • Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R.
    • J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.
    • Practice Guideline, NCCN Guidelines
    • AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.
    • Liedtke C, Thill M, Hanf V, Schütz F; AGO Breast Committee.
    • Breast Care (Basel). 2014 Jul;9(3):189-200. doi: 10.1159/000363591.
    • USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History.
    • Surabhi Dangi-Garimella.
    • OncLive, 2014 Jun 11.
    • Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
    • Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK.
    • Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.
    • Hereditary gynecologic cancers.
    • Mutch D, Denny L, Quinn M; FIGO Committee on Gynecologic Oncology.
    • Int J Gynaecol Obstet. 2014 Mar;124(3):189-92. doi: 10.1016/j.ijgo.2013.12.001. Epub 2013 Dec 21.
    • Practice Guideline
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
    • Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.
    • Ann Intern Med. 2014 Feb 18;160(4):255-66.
    • Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4). doi: 10.7326/P14-9008.

    Systematic Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2014 Feb 18;160(4):271-81.

    Patient Education Handout:

    Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4):I-16.

    Practice Guideline:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.

    • High-risk women should have BRCA testing.
    • [No authors listed]
    • Cancer Discov. 2014 Feb;4(2):139. doi: 10.1158/2159-8290.CD-NB2014-003. Epub 2014 Jan 16.
    • News
    • Risk management options elected by women after testing positive for a BRCA mutation.
    • Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.
    • Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
    • U.S. Preventive Services Task Force Finds Benefit in Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer for Small Group of High-Risk Women.
    • [No author given]
    • Yale Cancer Genetic Counseling. 2014 Jan 2.
    • Familial breast cancer: summary of updated NICE guidance.
    • Evans DG, Graham J, O'Connell S, Arnold S, Fitzsimmons D.
    • BMJ. 2013 Jun 25;346:f3829. doi: 10.1136/bmj.f3829.
    • Practice Guideline
    • NICE recommends preventive drugs for breast cancer.
    • Wise J.
    • BMJ. 2013 Jun 25;346:f4116. doi: 10.1136/bmj.f4116.
    • News